4//SEC Filing
Valeant Pharmaceuticals International, Inc. 4
Accession 0000885590-13-000072
$BHCCIK 0000885590operating
Filed
Aug 13, 8:00 PM ET
Accepted
Aug 14, 5:28 PM ET
Size
12.0 KB
Accession
0000885590-13-000072
Insider Transaction Report
Form 4
Wechsler Daniel Mark
EVO, Co. Grp. Chmn, Eye Health
Transactions
- Award
Restricted Share Units
2013-08-12+31,600→ 31,600 totalExercise: $0.00→ Common Shares, no par value (31,600 underlying) - Award
Non-Qualified Stock
2013-08-12+82,000→ 82,000 totalExercise: $101.87From: 2017-08-12Exp: 2023-08-12→ Common Shares, no par value (82,000 underlying)
Footnotes (3)
- [F1]Each Restricted Share Unit ("RSUs") represents a contingent right to receive between zero and three common shares, no par value, of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (2).
- [F2]The performance based RSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $93.84 each of three measurement dates: 25% would vest on May 12, 2016, 50% on August 12, 2016 and 25% on November 12, 2016, with early vesting possible at higher TSR levels.
- [F3]The options vest 25% per year for 4 years starting from the date of grant with the first vest date falling on the first anniversary of the grant, the second vest date falling on the second anniversary of the grant, the third vest date falling on the third anniversary of the grant and the fourth vest date falling on the fourth anniversary of the grant.
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000885590
Filing Metadata
- Form type
- 4
- Filed
- Aug 13, 8:00 PM ET
- Accepted
- Aug 14, 5:28 PM ET
- Size
- 12.0 KB